190 related articles for article (PubMed ID: 32800789)
21. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
[TBL] [Abstract][Full Text] [Related]
22. Autophagy and cancer: Can tetrandrine be a potent anticancer drug in the near future?
Bhagya N; Chandrashekar KR
Biomed Pharmacother; 2022 Apr; 148():112727. PubMed ID: 35219119
[TBL] [Abstract][Full Text] [Related]
23. Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy.
Liu T; Liu X; Li W
Oncotarget; 2016 Jun; 7(26):40800-40815. PubMed ID: 27027348
[TBL] [Abstract][Full Text] [Related]
24. Cepharanthine: An update of its mode of action, pharmacological properties and medical applications.
Bailly C
Phytomedicine; 2019 Sep; 62():152956. PubMed ID: 31132753
[TBL] [Abstract][Full Text] [Related]
25. Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21.
Mei L; Chen Y; Wang Z; Wang J; Wan J; Yu C; Liu X; Li W
Br J Pharmacol; 2015 May; 172(9):2232-45. PubMed ID: 25521075
[TBL] [Abstract][Full Text] [Related]
26. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
Evangelisti C; Evangelisti C; Chiarini F; Lonetti A; Buontempo F; Bressanin D; Cappellini A; Orsini E; McCubrey JA; Martelli AM
Int J Oncol; 2014 Sep; 45(3):909-18. PubMed ID: 24968804
[TBL] [Abstract][Full Text] [Related]
28. Synergistic inhibition of HTLV-1-infected cell proliferation by combination of cepharanthine and a tetramethylnaphthalene derivative.
Toyama M; Hamasaki T; Uto T; Aoyama H; Okamoto M; Hashmoto Y; Baba M
Anticancer Res; 2012 Jul; 32(7):2639-45. PubMed ID: 22753721
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory effects and mechanisms of plant alkaloid tetrandrine in autoimmune diseases.
Lai JH
Acta Pharmacol Sin; 2002 Dec; 23(12):1093-101. PubMed ID: 12466046
[TBL] [Abstract][Full Text] [Related]
30. Zebrafish screen identifies novel compound with selective toxicity against leukemia.
Ridges S; Heaton WL; Joshi D; Choi H; Eiring A; Batchelor L; Choudhry P; Manos EJ; Sofla H; Sanati A; Welborn S; Agarwal A; Spangrude GJ; Miles RR; Cox JE; Frazer JK; Deininger M; Balan K; Sigman M; Müschen M; Perova T; Johnson R; Montpellier B; Guidos CJ; Jones DA; Trede NS
Blood; 2012 Jun; 119(24):5621-31. PubMed ID: 22490804
[TBL] [Abstract][Full Text] [Related]
31. Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice.
Wu JM; Chen Y; Chen JC; Lin TY; Tseng SH
Cancer Lett; 2010 Jan; 287(2):187-95. PubMed ID: 19586712
[TBL] [Abstract][Full Text] [Related]
32. Tetrandrine may treat membranous glomerulopathy via P13K/Akt signaling pathway regulation: therapeutic mechanism validation using Heymann nephritis rat model.
Yin J; Lin J; Yu J; Wei X; Zhu B; Zhu C
Bioengineered; 2021 Dec; 12(1):6499-6515. PubMed ID: 34463195
[TBL] [Abstract][Full Text] [Related]
33. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
[TBL] [Abstract][Full Text] [Related]
34. Anticancer activity of tetrandrine by inducing pro-death apoptosis and autophagy in human gastric cancer cells.
Bai XY; Liu YG; Song W; Li YY; Hou DS; Luo HM; Liu P
J Pharm Pharmacol; 2018 Aug; 70(8):1048-1058. PubMed ID: 29770446
[TBL] [Abstract][Full Text] [Related]
35. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
[TBL] [Abstract][Full Text] [Related]
36. Tetrandrine prevents bone loss in sciatic-neurectomized mice and inhibits receptor activator of nuclear factor κB ligand-induced osteoclast differentiation.
Takahashi T; Tonami Y; Tachibana M; Nomura M; Shimada T; Aburada M; Kobayashi S
Biol Pharm Bull; 2012; 35(10):1765-74. PubMed ID: 23037166
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
38. Tetrandrine down-regulates ERK/NF-κB signaling and inhibits activation of mesangial cells.
Wu CJ; Wang YH; Lin CJ; Chen HH; Chen YJ
Toxicol In Vitro; 2011 Dec; 25(8):1834-40. PubMed ID: 22001142
[TBL] [Abstract][Full Text] [Related]
39. Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells.
Sun YF; Wink M
Phytomedicine; 2014; 21(8-9):1110-9. PubMed ID: 24856768
[TBL] [Abstract][Full Text] [Related]
40. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.
Tosello V; Saccomani V; Yu J; Bordin F; Amadori A; Piovan E
Oncotarget; 2016 Jul; 7(29):45715-45729. PubMed ID: 27304189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
